HAYWARD, Calif., July 27 /PRNewswire-FirstCall/ -- Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation, today announced it will release its second quarter 2010 financial report after market close on Wednesday, August 4, 2010. Anthera will host a conference call at 5 pm Eastern Time in conjunction with the release.
Conference Call Access: | |
Date: August 4, 2010 | |
Time: 5:00 pm Eastern Time | |
Domestic Dial-in: (877) 312-8807 | |
International Dial-in: (253) 237-1190 | |
Passcode: 90538418 | |
To access the 24-hour audio replay, U.S. and Canadian participants may dial (800) 642-1687; international participants may dial (706) 645-9291. The conference ID for the replay is 90538418. The audio replay will be available until August 11, 2010. This conference call will be webcast live and archived on Anthera’s website until August 4, 2011, www.anthera.com.
About Anthera Pharmaceuticals
Anthera Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation, including cardiovascular and autoimmune diseases. Anthera has one Phase 3 clinical program, A-002, and two Phase 2 clinical programs, A-623 and A-001. A-002 and A-001 inhibit a novel enzyme target known as secretory phospholipase A2, or sPLA2. Elevated levels of sPLA2 have been implicated in a variety of acute inflammatory conditions, including acute coronary syndrome and acute chest syndrome, as well as chronic diseases such as stable coronary artery disease (CAD). Anthera’s Phase 2 product candidate, A-623, targets elevated levels of B-lymphocyte stimulator, or BLyS, which has been associated with a variety of B-Cell mediated autoimmune diseases, including systemic lupus erythematosus, or lupus. For more information, please visit www.anthera.com.
CONTACT: Juliane Snowden of Burns McClellan, Inc., jsnowden@burnsmc.com or 212.213.0006.
SOURCE Anthera Pharmaceuticals, Inc.
